Odyssey Therapeutics

About:

Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.

Website: https://odysseytx.com

Twitter/X: odyssey_tx

Top Investors: General Catalyst, Fidelity, OrbiMed, Alexandria Venture Investments, Foresite Capital

Description:

Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. The company's integrated drug-hunting engine is designed to accelerate drug discovery by unlocking targets with great potential and minimizing attrition.

Total Funding Amount:

$487M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2021-01-01

Founders:

David Pompliano, Gary Glick

Number of Employees:

11-50

Last Funding Date:

2023-12-05

IPO Status:

Private

© 2025 bioDAO.ai